Novel Therapies Show Early Promise in Advanced Gastroesophageal Cancers
Results of two early-phase trials offered a glimpse of promising new agents in the pipeline for advanced gastroesophageal cancer. In a phase II study, incorporating an investigational PD-1 inhibitor and anti-T-cell immunoglobulin and ITM domain (TIGIT) monoclonal antibody into standard first-line chemotherapy showed promising activity in advanced gastroesophageal adenocarcinoma, reported Yelena Janjigian, MD, from Memorial […]